Alchem ups sennoside production in face of pharma demand

By Natalie Morrison & Gareth Macdonald

- Last updated on GMT

Related tags United states

Senna leaves and pods
Senna leaves and pods
Alchem International has expanded its sennosides production facility in India in a bid to meet pharma demand.

The firm – which makes the natural laxative product using its own cultivated senna leaves and pods – will up its production to more than 75 tons per year.

Speaking to, a spokespman at the facility in Neemrana, India, said the move was a result of high demand for sennosides from drugmakers in the US and Europe.

The company said its high good manufacturing practice (GMP) compliance and regular customer audits have driven demand for its production in particular, which creates 60 per cent purity USP (United States Pharmacopoeia) grade sennosides.

“Over the years, as regulatory focus on sennosides has increased globally, a need for high quality, regulatory compliant, drug master file (DMF) supported sennosides has emerged from the United States and Europe.  In addition the aging population in these countries has also led to an increase in the volume requirements,”​ the spokesman told us.

The expansion

As part of the expansion, the firm has made the switch from batch to continuous production, and has installed computer controlled manufacturing equipment.

“For this reason many instrumentation engineers, statistical analysts have been included in our team of engineers, chemists and quality staff,”​ the spokesman added. 

The firm also recently opened a new US liasons office, and has established a local stock of the product, in a bid to help the supply chain and grow business with US customers.

In a statement, president of Alchem Raman Mehta said: "With our long-time North American distributor, Ampak in New York, and our recently opened US liaison office, we're able to better serve our North American customers by offering local inventory of sennosides and technical support.”

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more